These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 7513678)

  • 1. Experience in treating benign prostatic hypertrophy with Sabal serrulata for one year.
    Romics I; Schmitz H; Frang D
    Int Urol Nephrol; 1993; 25(6):565-9. PubMed ID: 7513678
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Sabal serrulata extract in the management of symptoms of prostatic hypertrophy].
    Kondás J; Philipp V; Diószeghy G
    Orv Hetil; 1997 Feb; 138(7):419-21. PubMed ID: 9091843
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sabal serrulata extract (Strogen forte) in the treatment of symptomatic benign prostatic hyperplasia.
    Kondás J; Philipp V; Diószeghy G
    Int Urol Nephrol; 1996; 28(6):767-72. PubMed ID: 9089044
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Benign prostatic hyperplasia--treatment with sabal fruit extract. A treatment study of 1,334 patients].
    Vahlensieck W; Völp A; Lubos W; Kuntze M
    Fortschr Med; 1993 Jun; 111(18):323-6. PubMed ID: 7689525
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Treatment of benign prostatic hyperplasia. Results of a treatment study with the phytogenic combination of Sabal extract WS 1473 and Urtica extract WS 1031 in urologic specialty practices].
    Schneider HJ; Honold E; Masuhr T
    Fortschr Med; 1995 Jan; 113(3):37-40. PubMed ID: 7534258
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enzyme activities in tissue of human benign prostatic hyperplasia after three months' treatment with the Sabal serrulata extract IDS 89 (Strogen) or placebo.
    Weisser H; Behnke B; Helpap B; Bach D; Krieg M
    Eur Urol; 1997; 31(1):97-101. PubMed ID: 9032543
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [An urodynamic study of patients with benign prostatic hypertrophy treated conservatively with phytotherapy or testosterone (author's transl)].
    Flamm J; Kiesswetter H; Englisch M
    Wien Klin Wochenschr; 1979 Sep; 91(18):622-7. PubMed ID: 90434
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of the sabal serrulata extract IDS 89 and its subfractions on 5 alpha-reductase activity in human benign prostatic hyperplasia.
    Weisser H; Tunn S; Behnke B; Krieg M
    Prostate; 1996 May; 28(5):300-6. PubMed ID: 8610056
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Drug therapy of benign prostatic hyperplasia].
    Vahlensieck W; Fabricius PG; Hell U
    Fortschr Med; 1996 Nov; 114(31):407-11. PubMed ID: 9036092
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Clinical evaluation of Cernilton in benign prostatic hypertrophy].
    Hayashi J; Mitsui H; Yamakawa G; Suga A; Kai A; Shimabukuro T; Yanagi K; Fujisawa S; Takihara H; Kaneda Y
    Hinyokika Kiyo; 1986 Jan; 32(1):135-41. PubMed ID: 2421560
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A multicentric, placebo-controlled, double-blind clinical trial of beta-sitosterol (phytosterol) for the treatment of benign prostatic hyperplasia. German BPH-Phyto Study group.
    Klippel KF; Hiltl DM; Schipp B
    Br J Urol; 1997 Sep; 80(3):427-32. PubMed ID: 9313662
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical relevance of growth factor antagonists in the treatment of benign prostatic hyperplasia.
    Desgrandchamps F
    Eur Urol; 1997; 32 Suppl 1():28-31. PubMed ID: 9218940
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Clinical study of Eviprostat for the treatment of benign prostatic hyperplasia].
    Song Y; Li NC; Wang XF; Ma LL; Wan B; Hong BF; Na YQ
    Zhonghua Nan Ke Xue; 2005 Sep; 11(9):674-6. PubMed ID: 16209208
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Prostaplant treatment of benign prostatic hyperplasia].
    Medvedev AA; Siniakova LA; Zaĭtsev AV
    Urologiia; 2000; (4):13-5. PubMed ID: 11186685
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current treatment of BPH.
    Roylance P; Gibelin B; Espié J
    Biomed Pharmacother; 1995; 49(7-8):332-8. PubMed ID: 8562858
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Saw palmetto. Serenoa repens. Also known as Serenoa serrulata, Sabal serrulata and the dwarf palm.
    Barnes J
    J Prim Health Care; 2009 Dec; 1(4):323. PubMed ID: 20690343
    [No Abstract]   [Full Text] [Related]  

  • 17. [A comparative study on different doses of cernilton for preventing the clinical progression of benign prostatic hyperplasia].
    Xu J; Qian WQ; Song JD
    Zhonghua Nan Ke Xue; 2008 Jun; 14(6):533-7. PubMed ID: 18649754
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term study to assess the efficacy of tamsulosin in the control of symptoms and complications developed in patients with symptomatic benign prostatic hyperplasia (OMNICONTROL study): first-year follow-up report.
    Palacio A; Hernández C; Marqués A; Prats J; Espinosa FJ
    Arch Esp Urol; 2004 May; 57(4):451-60. PubMed ID: 15270291
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Current drug therapy of benign prostatic hyperplasia].
    Schmidbauer CP; Madersbacher S
    Wien Med Wochenschr; 1996; 146(8):161-4. PubMed ID: 8767400
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Doxazosin in the gastrointestinal therapeutic system (GITS) and doxazosin standard in patients with benign prostatic hyperplasia. Double-blind trial of efficacy and tolerability].
    Gratzke P; Kirby RS
    Fortschr Med Orig; 2000 Jul; 118 Suppl 2():83-92. PubMed ID: 15700491
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.